Hot Stocks
08:22 EDT Mind Medicine says MM120 showed statistically significant efficacy in Phase 2 - Mind Medicine presented data from MMED008, its Phase 2b study of MM120 in the treatment of generalized anxiety disorder in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. the company said in a statement. MM120 demonstrated rapid, clinically meaningful, and statistically significant improvements on the Hamilton Anxiety rating scale compared to placebo at week 4, the study's primary endpoint, and maintained durability of response to week 12, according to the company. MM120 was administered as a single dose in a monitored clinical setting, with no additional therapeutic intervention, to demonstrate the medication's effect. MM120 100 microgram - the dose with optimal clinical activity observed in the study - demonstrated a 7.7-point improvement over placebo at week 12, with a 65% clinical response rate and a 48% clinical remission rate sustained to week 12.
|
